MDM2 and cancer: It is known that TP53 contains gain of function mutations associate with increased expression of TP53 [29, 30] through down-regulation of downstream targets such as MDM2/MDM4, which suppress the expression of TP53. However, it is not well investigated whether different mutations in TP53 exhibit different functions across different cancer types.